NASDAQ: KARD · Life Sciences · 4 alerts · CIK 2123613
Share price
$12.85Close, Nov 16
Market cap
$1.2B
Shares outstanding
93.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kardigan, Inc. filings on SEC EDGAR ↗
Kardigan, Inc. is a clinical-stage biopharmaceutical company focusing on cardiovascular diseases with lead candidates Danicamtiv, Ataciguat, and Tonlamarsen. As of November 2026, the company is an emerging growth company with 93,597,398 shares of common stock outstanding and continues to anticipate significant financial losses as it funds its clinical trials and Prolaio platform development.
Kardigan, Inc. reported third quarter 2026 financial results, ending the period with $591.4 million in cash to fund operations through 2027. The company achieved significant clinical milestones, including completing enrollment in the Phase 2b portion of its danicamtiv KINSHIP-DCM trial and the Phase 2b KATALYST-AV trial for ataciguat. Topline data for the danicamtiv trial is expected in the second quarter of 2027.
Term
Q3 2026
“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options. Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.”
Tassos Gianakakos, co-founder, chief executive officer and board chair
Kardigan, Inc. has completed enrollment for its Phase 2b KATALYST-AV trial evaluating ataciguat in patients with aortic stenosis. The company also updated its trial protocol to assess the primary endpoint of aortic valve calcium at week 48 instead of earlier, based on real-world data analysis of disease progression. Topline data from the trial is now expected in the second half of 2027.